Nothing Special   »   [go: up one dir, main page]

CR20120190A - INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA - Google Patents

INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA

Info

Publication number
CR20120190A
CR20120190A CR20120190A CR20120190A CR20120190A CR 20120190 A CR20120190 A CR 20120190A CR 20120190 A CR20120190 A CR 20120190A CR 20120190 A CR20120190 A CR 20120190A CR 20120190 A CR20120190 A CR 20120190A
Authority
CR
Costa Rica
Prior art keywords
coa carboxylase
pirazoloespirocetona
acetil
inhibitors
compound
Prior art date
Application number
CR20120190A
Other languages
English (en)
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20120190A publication Critical patent/CR20120190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del compuesto, el la que R1, R1, R3 y R4 son como se describen en el presente documento; composiciones farmacèuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o transtornos modulados por la inhibiciòn de una enzima acetil-CoA carboxilasa en un animal.
CR20120190A 2009-11-10 2012-04-18 INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA CR20120190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10

Publications (1)

Publication Number Publication Date
CR20120190A true CR20120190A (es) 2012-05-24

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120190A CR20120190A (es) 2009-11-10 2012-04-18 INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA

Country Status (39)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2947082A1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101550557B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HK (1) HK1173724A1 (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
JP5114610B1 (ja) 2009-11-10 2013-01-09 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
EP2952514A1 (en) * 2010-10-29 2015-12-09 Pfizer Inc N1/n2-lactam acetyl-coa carboxylase inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
RS54526B1 (en) * 2011-04-22 2016-06-30 Pfizer Inc. USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
IL314671A (en) 2011-09-02 2024-10-01 Incyte Holdings Corp Heterocycloamines as 13-fold inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
AU2014236711A1 (en) 2013-03-14 2015-09-17 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3043800A1 (en) 2013-09-12 2016-07-20 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9676770B2 (en) 2014-09-16 2017-06-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9758517B2 (en) * 2014-09-17 2017-09-12 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6539285B2 (ja) 2014-11-10 2019-07-03 国立大学法人横浜国立大学 酸素発生用アノード
LT3262046T (lt) 2015-02-27 2021-01-11 Incyte Corporation Pi3k inhibitoriaus druskos ir jų gamybos būdai
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
EP3644998B1 (en) 2017-06-30 2024-04-10 Quixgen, Inc. Novel spirolactone compounds
EP3713942B8 (en) 2017-11-21 2023-04-12 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
EP4154880A4 (en) 2020-05-21 2024-06-05 Shionogi & Co., Ltd MEDICINES FOR THE TREATMENT OF FATTY LIVER DISEASE
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
EP4434520A1 (en) 2021-11-19 2024-09-25 Shionogi & Co., Ltd. Pharmaceutical for treating heart disease or skeletal muscle disease
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
RS63203A (en) 2001-02-28 2006-12-15 Merck & Co.Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2006270145B2 (en) 2005-07-19 2011-04-14 Msd K.K. Spirochromanone derivatives as acetyl coenzyme a carboxylase (ACC) inhibitors
CA2617042A1 (en) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
JP2009515971A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト
EP1991536A2 (en) 2006-02-15 2008-11-19 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EP2097420B1 (en) 2006-11-29 2012-04-04 Pfizer Products Inc. Spiroketone inhibitors of acetyl-coa carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
MX2009010951A (es) * 2007-04-12 2009-10-29 Pfizer Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c.
US20100211592A1 (en) * 2007-07-20 2010-08-19 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja) * 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
AU2009266730B2 (en) 2008-07-04 2013-07-18 Msd K.K. Novel spirochromanone carboxylic acids
CA2730493A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
LT3061760T (lt) * 2008-09-18 2018-02-26 Auspex Pharmaceuticals, Inc. Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
EP2499140A1 (en) 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5114610B1 (ja) * 2009-11-10 2013-01-09 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
RS54526B1 (en) * 2011-04-22 2016-06-30 Pfizer Inc. USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS

Also Published As

Publication number Publication date
HRP20140025T1 (hr) 2014-02-14
US8802690B2 (en) 2014-08-12
CA2778886C (en) 2014-01-07
US8288405B2 (en) 2012-10-16
US8507681B2 (en) 2013-08-13
JP2013510192A (ja) 2013-03-21
CU20120071A7 (es) 2013-05-31
KR20120099460A (ko) 2012-09-10
UY33020A (es) 2011-06-30
IL219373A (en) 2014-04-30
US20130030181A1 (en) 2013-01-31
US9139587B2 (en) 2015-09-22
EP2676958B1 (en) 2015-07-01
CL2012000999A1 (es) 2012-07-20
AU2010317501A1 (en) 2012-05-17
ZA201204231B (en) 2013-02-27
UA102336C2 (uk) 2013-06-25
US20140288111A1 (en) 2014-09-25
GEP20146169B (en) 2014-09-25
HK1173724A1 (en) 2013-05-24
US20130296319A1 (en) 2013-11-07
KR101478517B1 (ko) 2015-01-02
TN2012000192A1 (fr) 2013-12-12
TW201127838A (en) 2011-08-16
KR101550557B1 (ko) 2015-09-04
DOP2012000128A (es) 2012-08-31
CO6541569A2 (es) 2012-10-16
CA2778886A1 (en) 2011-05-19
PT2499139E (pt) 2014-02-10
AP3283A (en) 2015-05-31
SI2499139T1 (sl) 2014-01-31
EP2499139B1 (en) 2013-12-11
WO2011058474A1 (en) 2011-05-19
ECSP12011880A (es) 2012-07-31
NZ599815A (en) 2013-04-26
NI201200089A (es) 2012-08-20
CN102695708B (zh) 2014-10-15
DK2499139T3 (da) 2014-01-27
RS53156B (en) 2014-06-30
PE20121469A1 (es) 2012-11-01
WO2011058474A8 (en) 2012-04-26
CN102695708A (zh) 2012-09-26
US20110111046A1 (en) 2011-05-12
EP2499139A1 (en) 2012-09-19
AU2010317501B2 (en) 2013-06-06
MX2012005429A (es) 2012-06-19
AP2012006269A0 (en) 2012-06-30
KR20140034919A (ko) 2014-03-20
IL219373A0 (en) 2012-06-28
JP5114610B1 (ja) 2013-01-09
EA020153B1 (ru) 2014-09-30
MA33734B1 (fr) 2012-11-01
TWI394756B (zh) 2013-05-01
PL2499139T3 (pl) 2014-04-30
HN2012000973A (es) 2015-03-02
BR112012011072A2 (pt) 2017-06-20
ES2444543T3 (es) 2014-02-25
EP2676958A1 (en) 2013-12-25
CU24077B1 (es) 2015-03-30
EP2947082A1 (en) 2015-11-25
EA201290191A1 (ru) 2012-12-28
AR078944A1 (es) 2011-12-14

Similar Documents

Publication Publication Date Title
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201390347A1 (ru) Лечение заболеваний
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
DOP2012000078A (es) Derivados de espirolactama y usos de los mismos
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
CY1114907T1 (el) N1-πυραζολοσπειροκετονης αναστολεις ακετυλ-coa καρβοξυλασης